Conversely, the cellular resistance to ferroptosis is enhanced by increased oncogenic KRAS; however, inhibitors of ferroptosis have demonstrated efficacy in treating cancers harboring KRAS mutations [13]. The gene discussed is KRAS; the disease is cancer.